7492
W. Wichitnithad et al. / Bioorg. Med. Chem. 19 (2011) 7482–7492
6. Binda, C.; Newton-Vinson, P.; Hubálek, F.; Edmondson, D. E.; Mattevi, A. Nat.
Struct. Biol. 2002, 9, 22.
7. Binda, C.; Hubálek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D. E.; Mattevi,
A. J. Med. Chem. 2005, 48, 8148.
8. Vintém, A. P.; Price, N. T.; Silverman, R. B.; Ramsay, R. R. Bioorg. Med. Chem.
2005, 13, 3487.
9. Rando, R. R.; Eigner, A. Mol. Pharmacol. 1977, 13, 1005.
10. Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Proc.
Natl. Acad. Sci. U.S.A. 2003, 100, 9750.
11. Paech, C.; Salach, J. I.; Singer, T. P. J. Biol. Chem. 1980, 255, 2700.
12. Cesura, A. M.; Gottowik, J.; Lahm, H. W.; Lang, G.; Imhof, R.; Malherbe, P.;
Röthlisberger, U.; Da Prada, M. Eur. J. Biochem. 1996, 236, 996.
13. Fu, R. C.; Liu, X.-F.; Chen, S. J. Neurochem. 1990, 55, 813.
14. Weyler, W.; Salach, J. I. J. Biol. Chem. 1985, 260, 13199.
15. Wu, H. F.; Chen, K.; Shih, J. C. Mol. Pharmacol. 1993, 43, 888.
16. Ramsay, R. R.; Jones, T. Z.; Hynson, R. M. Med. Sci. Monit. 2005, 11, SR15.
17. McDonald, G. R.; Olivieri, A.; Ramsay, R. R.; Holt, A. Pharmacol Res. 2010, 62,
475.
specific brain regions and standards were diluted in PBS containing
0.5% Triton X-100. Nonspecific binding was blocked with 5% nonfat
dry milk in PBS and then aliquots of the homogenates and stan-
dards were added to the wells and incubated. Following four
sequential washes, a different host specifies antibody to GFAP or
TH from the ones used as ‘capture’ were added to ‘sandwich’ the
antigen between the antibodies. An alkaline phosphatase or perox-
idase conjugated secondary with fluorogenic substrate was used as
a reporter for quantification of GFAP and TH, respectively, via spec-
trophotometry and fluorometry.
4.23. Measurement of catecholamines and catecholamine
metabolites
18. Jones, T. Z.; Giurato, L.; Guccione, S.; Ramsay, R. R. FEBS J. 2007, 274, 1567.
19. Bonivento, D.; Milczek, E. M.; McDonald, G. R.; Binda, C.; Holt, A.; Edmondson,
D. E.; Mattevi, A. J. Biol. Chem. 2010, 285, 36849.
20. Mabic, S.; Castagnoli, N. J. Med. Chem. 1996, 39, 3694.
21. Rajeswaran, W.; Cao, Y.; Huang, X.; Wroblewski, E.; Colclough, T.; Lee, S.; Liu,
F.; Nagy, P.; Ellis, J.; Levine, B.; Nocka, K.; Messer, W. J. Med. Chem. 2001, 44,
4563.
Dopamine, serotonin and their metabolites were quantified by
high performance liquid chromatography with electrochemical
detection (HPLC_EC; Waters). Striata were homogenized in
300 lL of ice-cold 0.2 M perchloric acid, containing 1 lM
dihydroxybenzylamine as internal standard, and centrifuged at
22. Glase, S. A.; Akunne, H. C.; Heffner, T. G.; Jaen, J. C.; MacKenzie, R. G.; Meltzer, L.
T.; Pugsley, T. A.; Smith, S. J.; Wise, L. D. J. Med. Chem. 1996, 39, 3179.
23. Yoon, K.; Wilson, T.; Williams, S.; Redda, K. Drugs Exp. Clin. Res. 2000, 26, 73.
24. Singer, T. P.; Salach, J. I.; Castagnoli, N., Jr.; Trevor, A. Biochem. J. 1986, 235, 785.
25. Manral, L.; Gupta, P. K.; Suryanarayana, M. V. S.; Ganesan, K.; Malhotra, R. C. J.
Thermal. Anal. Calorimetry 2009, 96, 531.
26. Wichitnithad, W.; McManus, T. J.; Callery, P. S. Rapid Commun. Mass Spectrom.
2010, 24, 2547.
27. Mabic, S.; Rimoldi, J. M.; Castagnoli, N., Jr. J. Label. Comp. Radiopharm. 1997, 39,
409.
28. Weissbach, H.; Smith, T. E.; Daly, J. W.; Witkop, B.; Udenfriend, S. J. Biol. Chem.
1960, 235, 1160.
29. Cheng, Y. C.; Prusoff, W. H. Biochem. Pharmacol. 1973, 22, 3099.
30. Castagnoli, N., Jr.; Rimoldi, J. M.; Bloomquist, J.; Castagnoli, K. P. Chem. Res.
Toxicol. 1997, 10, 924.
10,000g for 10 min at 4 °C. The supernatant was filtered through
a 0.2 lm membrane, and 10 lL was injected from a temperature-
controlled (4 °C) automatic sample injector (Waters 717 plus Auto-
sampler) connected to a Waters 515 HPLC pump. Analytes were
separated on a C18 reverse-phase column (LC-18RP; Waters SYM-
METRY, 25 cm ꢁ 4.6 mm;
5 lm), electrochemically detected
(Waters 464 Pulsed Electrochemical Detector; range 10 nA, poten-
tial +0.7 V), and analyzed using Millennium software (Waters). The
mobile phase, pH 3.0, for isocratic separation consisted of dibasic
sodium phosphate (75 mM), octane sulfonic acid (1.7 mM), aceto-
nitrile (10% v/v), and EDTA (25 lM). Flow rate was maintained at
1 mL/min, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC),
homovanillic acid (HVA), serotonin, and 5-hydroxyindoleacetic
acid (5-HIAA) standards (0.5–25 pmol) were prepared in 0.2 M per-
chloric acid containing dihydroxybenzylamine. Recovery of each
analyte was adjusted with respect to the internal standard and
quantified from a standard curve. The levels of dopamine, seroto-
nin and their metabolites were expressed as micrograms per gram
of wet tissue.
31. Salach, J. I.; Singer, T. P.; Castagnoli, N., Jr.; Trevor, A. Biochem. Biophys. Res.
Commun. 1984, 125, 831.
32. Kitz, R.; Wilson, I. B. J. Biol. Chem. 1962, 237, 3245.
33. Silverman, R. B.; Yamasaki, R. B. Biochemistry 1984, 23, 1322.
34. Ungar, F.; Alivisatos, S. G. Res. Commun. Chem. Pathol. Pharmacol. 1976, 13, 449.
35. Cesura, A. M.; Muggli-Maniglio, D.; Lang, G.; Imhof, R.; Da Prada, M. J. Neural.
Transm. Suppl. 1990, 32, 165.
36. Milczek, E. M.; Bonivento, D.; Binda, C.; Mattevi, A.; McDonald, I. A.;
Edmondson, D. E. J. Med. Chem. 2008, 51, 8019.
37. Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. J. Mol.
Biol. 2004, 338, 103.
38. Morrison, J. F.; Walsh, C. T. Adv. Enzymol. Relat. Areas Mol. Biol. 1988, 61, 201.
39. Kinemuchi, H.; Arai, Y.; Oreland, L.; Tipton, K. F.; Fowler, C. J. Biochem.
Pharmacol. 1982, 31, 959.
40. Anderson, M. C.; Waldmeier, P. C.; Tipton, K. F. Biochem. Pharmacol. 1991, 41,
1871.
41. Holt, A.; Baker, G. B. NaunynSchmiedebergs Arch. Pharmacol. 1996, 354, 17.
42. Silverman, R. B.; Hiebert, C. K.; Vazquez, M. L. J. Biol. Chem. 1985, 260, 14648.
43. Fuller, R. W.; Hemrick-Luecke, S. K. J. Pharm. Exp. Ther. 1985, 232, 696.
44. Hiebert, C. K.; Sayre, L. M.; Silverman, R. B. J. Biol. Chem. 1989, 264, 21516.
45. Anderson, M. C.; Hasan, F.; McCrodden, J. M.; Tipton, K. F. Neurochem Res. 1993,
18, 1145.
Acknowledgments
Financial support was provided by the Thailand Research Fund
through the Royal Golden Jubilee Ph.D Program (Grant No. PHD/
0217/2548) to W. Wichitnithad and U. Nimmannit. Technical assis-
tance from James D. Thornton and Rachel Brown is appreciated.
Support from the mass spectrometry laboratory at West Virginia
University is acknowledged.
46. Efange, S. M. N.; Michelson, R. H.; Remmel, R. P.; Boudreau, R. J.; Dutta, A. K.;
Freshler, A. J. Med. Chem. 1990, 33, 3133.
47. Cui, L.; Sapagovas, V.; Lattermann, G. Liquid Crystals 2002, 29, 1121.
48. Ablordeppey, S. Y.; Fischer, J. B.; Burke Howie, K. J.; Glennon, R. A. Med. Chem.
Res. 1992, 2, 368.
49. Takemura, S.; Miki, Y.; Uono, M.; Yoshimura, K.; Kuroda, M.; Suzuki, A. Chem.
Pharm. Bull. 1981, 10, 3026.
50. Iorio, M. A.; Ciuffa, P.; Damia, G. Tetrahedron 1970, 26, 5519.
51. Horrillo-Martinez, P.; Hultzsch, K. C.; Gil, A.; Branchadell, V. Eur. J. Org. Chem.
2007, 3311.
Supplementary data
Supplementary data associated with this article can be found, in
include MOL files and InChiKeys of the most important compounds
described in this article.
52. Rui-Bin, S.; Jin, L.; Xin, L.; Bo-Yi, Q. ActaPharmacol. Sin. 2001, 22, 639.
53. O’Callaghan, J. P.; Miller, D. B.; Reinhard, J. F., Jr. Brain Res. 1990, 521, 73.
54. O’Callaghan, J. P. Neurotoxicol. Teratol. 1991, 13, 275.
55. O’Callaghan, J. P. In Current Protocols in Toxicology; Costa, L. G., Ed.; John Wiley
& Sons: New York, 2002; pp 12.8.11–12.8.12.
References and notes
1. Bolasco, A.; Carradori, S.; Fioravanti, R. Expert Opin. Ther. Patents 2010, 20, 909.
2. Youdim, M. B. H.; Edmondson, D.; Tipton, K. F. Nat. Rev. Neurosci. 2006, 7, 295.
3. Stahl, S. M.; Felker, A. CNS Spectr. 2008, 10, 855.
4. Edmondson, D. E.; Binda, C.; Mattevi, A. Arch. Biochem. Biophys. 2007, 464, 269.
5. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Proc.
Natl. Acad. Sci. U.S.A. 2005, 102, 12684.
56. Sriram, K.; Benkovic, S. A.; Hebert, M. A.; Miller, D. B.; O’Callaghan, J. P. J. Biol.
Chem. 2004, 279, 19936.